Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 313

Next Previous
Drug Profile

CM 313

Alternative Names: CM-313; CM313(SC)

Latest Information Update: 19 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer Institute of Hematology & Blood Diseases Hospital; KeyMed Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic thrombocytopenic purpura
  • Phase I/II Systemic lupus erythematosus; Thrombocytopenia
  • Phase I Lymphoma; Multiple myeloma

Most Recent Events

  • 14 May 2026 KeyMed Biosciences withdraws a phase I/II trial for Precursor T-cell lymphoblastic leukaemia lymphoma (Combination therapy, First-line therapy or greater, In adults, In the elderly, In children, In adolescents) prior to enrolment due to drug-associated adverse reactions (NCT07585734)
  • 01 Apr 2025 Sichuan Provincial People's Hospital plans a clinical trial for Pemphigus (Combination therapy) in China (Parenteral) (NCT06904040)
  • 25 Mar 2025 Phase-I/II clinical trials in Thrombocytopenia in China (SC) (NCT06792019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top